# US 2012/0252759 A1 · Thiazole derivatives for the treatment of diseases such as cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252759 A1
- Document ID: US20120252759A1
- Status: Published application
- Kind: A1
- Application number: 13/515,537
- Filed: 2010-11-09
- Published: 2012-10-04
- Earliest claimed: 2009-12-14
- Assignees: Merck Patent Gesellschaft Mit Beschranker Hafting
- Inventors: Timo Heinrich; Hannes Koolman
- Web page: https://patentgrep.com/patent/US20120252759A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 277/48: by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of the formula Ia and Ib, in which R1, R1′, R2, R3, R5, R6 and R7 have the meanings indicated in claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumours.

## Claims

### Claim 1

Compounds of the formula Ia and Ib
in which
R1 denotes H, (CH2)nAr or (CH2)nHet,
R1′ denotes H or A,
R2 denotes H, A, Hal, (CH2)nHet1, (CH2)nHet3, —C≡C—Ar, (CH2)nAr2, NHCONHAr, COA, COOH, COOA, COHet1, COAr2, CONH2, CONHA, CONA2, SO2NH2, SO2NHA, S(O)mA, NHCOA, SO2NHA, SO2NA2, SO2NHHet1, SO2NHAr2 or
R3 denotes NHCOOA′ or NH2,
R4 denotes (CH2)nAr, SiA3 or (CH2),Het4,
R5 denotes H, Hal or (CH2)nHet3,
R6 denotes H, —C≡C—R4 or Hal,
R7 denotes H, A, Ar or Het1,
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, CN, NO2, SO2A, COOH, COOA, NH2, NHA, NA2, NHCH2Ar1, CHO, COA, CHO, CONH2, CONHA, CONA2, Het, SO2NH2, SO2NHA, S(O)mA and/or NHCOA,
Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NH2, NHA, NA2, COOH, COOA, CONH2, CONHA, CONA2, CONHAr, CONHHet4, S(O)mA and/or NHCH2Ar1,
Ar1 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH and/or OA,
Ar2 denotes phenyl which is monosubstituted by NHCONHHet4,
Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, COOA, NH2, NHR8 and/or (CH2)nHet2,
R8 denotes H, A, Ar1 or Het4,
R9, R10 each, independently of one another, denote H or Hal,
R11 denotes H or A′,
Het2 denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, COOA and/or NH2,
Het3 denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by NH2,
Het4 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, Ar1, NH2, NHCH2Ar1 and/or ═O,
A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and/or in which one or two non-adjacent CH and/or CH2 groups may be replaced by O, NH, NA′, S, SO, SO2 and/or by CH═CH groups,
or
cyclic alkyl having 3-7 C atoms,
A′ denotes unbranched or branched alkyl having 1-4 C atoms,
Hal denotes F, Cl, Br or I,
m denotes 0, 1 or 2,
n denotes 0, 1, 2, 3 or 4,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 2 (depends on 1)

Compounds according to claim 1 in which
R1 denotes H, (CH2)nAr or (CH2)nHet,
R1′ denotes H,
R2 denotes H, Hal, (CH2)nHet1, (CH2)nHet3 or —C≡C—Ar,
R3 denotes NHCOOA′ or NH2,
R4 denotes (CH2)nAr, SiA3 or (CH2)nHet4,
R5 denotes H or (CH2)nHet3,
R6 denotes H, —C≡C—R4 or Hal,
R7 denotes H,
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, CN, NO2, SO2A, COOH, COOA, NH2, NHA, NA2, NHCH2Ar1, CHO, COA, CHO, CONH2, CONHA, CONA2, SO2NH2, SO2NHA and/or NHCOA,
Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NH2 and/or NHCH2Ar′,
Ar1 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH and/or OA,
Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NH2 and/or CH2Het2,
Het2 denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A and/or NH2,
Het3 denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by NH2,
Het4 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NH2, NHCH2Ar′ and/or ═O,
A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br,
A′ denotes unbranched or branched alkyl having 1-4 C atoms,
Hal denotes F, Cl, Br or I,
n denotes 0, 1, 2, 3 or 4,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 3 (depends on 1)

Compounds according to claim 1 in which
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA, NH2, NHA, NA2 and/or NHCH2Ar1,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 4 (depends on 1)

Compounds according to claim 1, in which
Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, quinolinyl, quinoxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl, indolyl or indazolyl, each of which is unsubstituted or mono- or disubstituted by NH2 and/or NHCH2Ar1,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 5 (depends on 1)

Compounds according to claim 1
in which
Ar1 denotes phenyl,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 6 (depends on 1)

Compounds according to claim 1.
in which
Het1 denotes piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, imidazolidinyl, oxazolidinyl, tetrahydropyranyl, thiazolyl, thiophenyl, furanyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, pyridinyl or pyrimidinyl, each of which is unsubstituted or mono- or disubstituted by NH2 and/or CH2Het2,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 7 (depends on 1)

Compounds according to claim 1
in which
Het2 denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, quinolinyl, quinoxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl, indolyl or indazolyl, each of which is unsubstituted or mono- or disubstituted by A and/or NH2,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 8 (depends on 1)

Compounds according to claim 1
in which
Het3 denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, quinolinyl, quinoxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl, indolyl or indazolyl, each of which is unsubstituted or mono- or disubstituted by A and/or NH2,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 9 (depends on 1)

Compounds according to claim 1
in which
Het4 denotes piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, imidazolidinyl, oxazolidinyl, tetrahydropyranyl, dihydroisoindolyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, quinolinyl, quinoxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl, indolyl or indazolyl, each of which is unsubstituted or mono- or disubstituted by NH2, NHCH2Ar1 and/or ═O,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 10 (depends on 1)

Compounds according to claim 1, selected from the group
No.
Name and/or structure
“1”
tert-Butyl N-(1,3-thiazol-4-yl)carbamate
“2”
tert-Butyl N-(5-iodo-1,3-thiazol-4-yl)carbamate
“A1”
5-(4-Fluorophenyl)-4H-pyrrolo[2,3-6]-1,3-thiazole
“A2”
5-Benzyl-4H-pyrrolo[2,3-d]thiazole
“A3”
4H-Pyrrolo[2,3-d]thiazole
“A4”
3-(4H-Pyrrolo[2,3-d]thiazol-5-yl)phenylamine
“A5”
Benzyl-[4-(4H-pyrrolo[2,3-d]thiazol-5-yl)pyridin-2-yl]amine
“A6”
Benzyl-[3-(4H-pyrrolo[2,3-d]thiazol-5-yl)phenyl]amine
“A7”
6-Benzyl-4H-pyrrolo[2,3-d]thiazole
“A8”
6-Benzyl-2-pyridin-4-yl-4H-pyrrolo[2,3-d]thiazole
“A9”
4-(4H-Pyrrolo[2,3-d]thiazol-5-yl)pyridin-2-ylamine
“A10”
2-Chloro-5-(4-fluorophenyl)-4H-pyrrolo[2,3-d]thiazole
“A11”
5-(4-Fluorophenyl)-2-(4-fluorophenylethynyl)-4H-pyrrolo-
[2,3-d]thiazole
“A12”
5-(4-Fluorophenyl)-2-morpholin-4-yl-4H-pyrrolo-
[2,3-d]thiazole
“A13”
5-(4-Fluorophenyl)-2-(4-pyridin-4-ylmethylpiperazin-1-yl)-4H-
pyrrolo[2,3-d]thiazole
“A14”
5-[5-(4-Fluorophenyl)-4H-pyrrolo[2,3-d]thiazol-2-yl]pyrimidin-2-ylamine
“A15”
tert-Butyl N-{5-[2-(4-fluorophenyl)ethynyl]-1,3-
thiazol-4-yl}carbamate
“A16”
tert-Butyl [5-(3-phenylprop-1-ynyl)thiazol-4-yl]carbamate
“A17”
tert-Butyl (5-triethylsilanylethynylthiazol-4-yl)carbamate
“A18”
tert-Butyl [5-(3-aminophenylethynyl)thiazol-4-yl]carbamate
“A19”
tert-Butyl [5-(3-benzylaminophenylethynyl)thiazol-4-yl]-
carbamate
“A20”
tert-Butyl [5-(2-benzylaminopyridin-4-ylethynyl)thiazol-4-yl]-
carbamate
“A21”
tert-Butyl [5-(1H-pyrrolo[2,3-b]pyridin-5-ylethynyl)thiazol-
4-yl]carbamate
“A22”
5-(1H-Pyrrolo[2,3-b]pyridin-5-ylethynyl)thiazol-4-ylamine
“A23”
tert-Butyl (2-pyridin-4-ylthiazol-4-yl)carbamate
“A24”
tert-Butyl N-(2-pyridin-4-yl-5-iodo-1,3-thiazol-4-yl)carbamate
“A25”
tert-Butyl [5-(3-morpholin-4-ylprop-1-ynyl)-2-pyridin-4-ylthiazol-4-yl]carbamate
“A26”
tert-Butyl {5-[3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)prop-1-
ynyl]thiazol-4-yl}carbamate
“A27”
3-(4-Aminothiazol-5-ylethynyl)phenol
“A28”
tert-Butyl [2-(2-aminopyridin-3-yl)-5-(4-fluorophenylethynyl)-
thiazol-4-yl]carbamate
“A29a”
tert-Butyl N-{2-chloro-5-[2-(4-fluorophenyl)ethynyl]-
1,3-thiazol-4-yl}carbamate
“A29”
tert-Butyl N-[2-(2-aminopyrimidin-5-yl)-5-[2-(4-
fluorophenyl)ethynyl]-1,3-thiazol-4-yl]carbamate
“A30”
3-[5-(4-Fluorophenyl)-4H-pyrrolo[2,3-d]thiazol-2-yl]pyridin-2-
ylamine
“A31”
3-[5-(4-Fluorophenyl)-4H-pyrrolo[2,3-d]thiazol-2-yl]-5-(1-
piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine
“A32”
6-(4,4-Dimethylpent-2-ynyl)-4H-pyrrolo[2,3-d]thiazole
“A33”
Methyl 2-tert-butyl-3-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-1H-
indole-5-carboxylate
“A34”
2-tert-Butyl-3-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-1H-
pyrrolo[2,3-b]pyridine
“A35”
6-(3,5-Difluorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A36”
6-(4-Methoxybenzyl)-4H-pyrrolo[2,3-d]thiazole
“A37”
6-(4-Bromobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A38”
6-(4-Isopropylbenzyl)-4H-pyrrolo[2,3-d]thiazole
“A39”
6-(4-Bromo-2-fluorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A40”
6-(4-tert-Butylbenzyl)-4H-pyrrolo[2,3-d]thiazole
“A41”
6-(2-Chlorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A42”
6-(4-Fluorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A43”
6-(3-Fluorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A44”
6-(2,3-Difluorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A45”
6-(2,4-Difluorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A46”
6-(2,5-Difluorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A47”
6-(3,4-Difluorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A48”
6-(6-Chloropyridin-3-ylmethyl)-4H-pyrrolo[2,3-d]thiazole
“A49”
6-(3-Chlorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A50”
6-(3,4-Dichlorobenzyl)-4H-pyrrolo[2,3-d]thiazole
“A51”
6-Benzyl-2-pyridin-3-yl-4H-pyrrolo[2,3-d]thiazole
“A52”
6-Benzyl-2-(1-methyl-1H-pyrazol-4-yl)-4H-pyrrolo-
[2,3-d]thiazole
“A53”
5-(6-Benzyl-4H-pyrrolo[2,3-d]thiazol-2-yl)pyridin-2-ylamine
“A54”
6-Prop-2-ynyl-4H-pyrrolo[2,3-d]thiazole
“A55”
3-(6-Benzyl-4H-pyrrolo[2,3-d]thiazol-2-yl)pyridin-2-ylamine
“A56”
6-Benzyl-2-(1H-pyrazol-4-yl)-4H-pyrrolo[2,3-d]thiazole
“A57”
6-Benzyl-2-(5-bromopyridin-3-yl)-4H-pyrrolo[2,3-d]thiazole
“A58”
6-Benzyl-2-pyrimidin-5-yl-4H-pyrrolo[2,3-d]thiazole
“A59”
Morpholin-4-yl-[3-(4H-pyrrolo[2,3-d]thiazole-6-ylmethyl)-1H-
indol-5-yl]methanone
“A60”
N-(2-Methoxyethyl)-3-(4H-pyrrolo[2,3-d]thiazole-6-ylmethyl)-
1H-indole-5-carboxamide
“A61”
N-(4-Fluorobenzyl)-3-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-
1H-indole-5-carboxamide
“A62”
N-(2-Aminoethyl)-2-[4-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-
1,2,3-triazol-1-yl]acetamide
“A63”
1-Piperazin-1-yl-2-[4-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-
1,2,3-triazol-1-yl]ethanone
“A64”
N-(Piperidin-4-yl)-2-[4-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-
1,2,3-triazol-1-yl]acetamide
“A65”
6-(1-Pyridin-3-ylmethyl-1H-1,2,3-triazol-4-ylmethyl) 4H-
pyrrolo[2,3-d]thiazole
“A66”
6-(1-Pyridin-4-ylmethyl-1H-1,2,3-triazol-4-ylmethyl) 4H-
pyrrolo[2,3-d]thiazole
“A67”
6-Benzyl-2-(5-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)-4H-
pyrrolo[2,3-d]thiazole
“A68”
6-Benzyl-2-(5-(1H-pyrazol-4-yl)pyridin-3-yl)-4H-pyrrolo[2,3-d]-
thiazole
“A69”
6-Benzyl-2-(5-(4-fluorophenyl)pyridin-3-yl)-4H-pyrrolo[2,3-d]-thiazole
“A70”
6-(5-Methanesulfonylthiophen-2ylmethyl)-4H-pyrrolo[2,3-d]-thiazole
“A71”
6-[1-(2-Morpholin-4-ylethyl)-1H-1,2,3-triazol-4-ylmethyl) 4H-pyrrolo[2,3-d]
thiazole
“A72”
6-Benzyl-2-{5-[1-((E)-3-phenylallyl)-1H-pyrazol-4-yl]pyridin-3-
yl}-4H-pyrrolo[2,3-d]thiazole
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 11 (depends on 1)

Process for the preparation of compounds of the formula Ia and Ib according to claim 1 and pharmaceutically usable salts, tautomers and stereoisomers thereof, characterised in that
a) for the preparation of a compound of the formula Ia′,
in which
R1 denotes Ar or Het,
R2 has the meanings indicated in claim 1, apart from Hal,
R7 denotes tert-butyloxycarbonyl,
and Ar and Het have the meanings indicated in claim 1,
a compound of the formula IIc
in which
R2 has the meaning indicated in claim 1, apart from Hal,
R7 denotes tert-butyloxycarbonyl,
is reacted with a compound of the formula IIIc
R1—CH═CH—CH2Br IIIc
in which R7 denotes Ar or Het,
and Ar and Het have the meanings indicated in claim 1,
and subsequently or simultaneously the tert-butyloxycarbonyl group is cleaved off,
or
b) for the preparation of a compound of the formula Ib′,
in which
R3 denotes NH—COO-tert-butyl,
R5 denotes H or (CH2)nHet3,
R6 denotes —C≡C—R4
and
n, R4 and Het3 have the meanings indicated in claim 1,
a compound of the formula IId
in which
R7 denotes tert-butyloxycarbonyl,
R5 denotes H or (CH″)nHet3,
and n and Het3 has the meaning indicated in claim 1,
is reacted with a compound of the formula Hid
H—C≡C—R4 IIId,
in which R4 has the meaning indicated in claim 1,
or
c) for the preparation of a compound of the formula Ib″
in which
R3 denotes NH—COO-tert-butyl,
R5 denotes Cl,
R6 denotes —C≡C—R4
and
R4 has the meaning indicated in claim 1,
a compound of the formula Ib″,
in which
R3 denotes NH—COO-tert-butyl,
R5 denotes H,
R6 denotes —C≡C—R4—
and
R4 has the meaning indicated in claim 1,
is reacted with N-chlorosuccinimide,
or
d) for the preparation of a compound of the formula Ib'
in which
R3 denotes NH—COO-tert-butyl,
R5 denotes (CH2)nHet3,
R6 denotes
and
n, R4 and Het3 have the meanings indicated in claim 1,
a compound of the formula Ib″
in which
R3 denotes NH—COO-ten-butyl,
R5 denotes Cl,
R6 denotes —C≡C—R4
and
R4 has the meaning indicated in claim 1,
is reacted with a compound of the formula IVa
L-(CH2)nR5
in which R5 denotes Het3,
n and Het3 have the meanings indicated in claim
and L denotes a boronic acid or boronic acid ester radical,
and subsequently or simultaneously the Boc group is cleaved off,
or
e) for the preparation of a compound of the formula Ia″
in which
RI denotes Ar or Het,
R2 denotes H, Cl, (CH2)nHet3
R7 denotes H
and n, Ar, Het and Het3 have the meanings indicated in claim 1,
a compound of the formula Ib'
in which
R3 denotes NH—COO-tert-butyl,
R5 denotes H, Cl, (CH2)nHet3,
R6 denotes —C≡C—R4
R4 denotes Ar or Het,
and Ar, Het, Het3 and R4 have the meanings indicated in claim 1,
is heated in the presence of a base,
or
f) for the preparation of a compound of the formula Ia″
in which
R7 denotes Ar or Het,
R2 denotes Het1
R7 denotes H
a compound of the formula Ia″
in which
R1 denotes Ar or Het,
R2 denotes Hal
R7 denotes H,
Ar and Het have the meanings indicated in claim 1,
is reacted with a compound of the formula Va
Het1-H Va
in which Het1 has the meaning indicated in claim 1,
and/or
a base or acid of the formula Ia or Ib is converted into one of its salts.

### Claim 12 (depends on 1)

Medicaments comprising at least one compound of the formula Ia or Ib according to claim 1 and/or pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

### Claim 13 (depends on 1)

Compounds according to claim 1 and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use for the preparation of a medicament for the treatment of tumours, cancer, tumour formation, growth and propagation, arteriosclerosis, ocular diseases, such as age-induced macular degeneration, choroidal neovascularisation and diabetic retinopathy, inflammatory diseases, arthritis, thrombosis, fibrosis, glomerulonephritis, neurodegeneration, psoriasis, restenosis, wound healing, transplant rejection, metabolic and diseases of the immune system, autoimmune diseases, cirrhosis, diabetes and diseases of the blood vessels.
